Related Experiment Video
Updated: Aug 19, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
[Suppressive effects of bisphosphonates on the vascular calcification in ESRD patients]
Kazuhiro Tamura1, Hirotake Hashiba, Hiroshi Kogo
1Department of Pharmacology, Tokyo University of Pharmacy & Life Science.
Insights
Etidronate may inhibit aortic calcification progression in hemodialysis patients. This finding suggests etidronate could help prevent cardiovascular and cerebrovascular diseases, major causes of death in this population.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Biochemistry
Context:
- Aortic calcification is a significant predictor of cardiovascular and cerebrovascular disease in hemodialysis patients.
- Vascular calcification contributes to increased mortality in patients undergoing renal replacement therapy.
Purpose:
- To investigate the effect of etidronate on the progression of aortic calcification in hemodialysis patients.
- To assess whether etidronate can mitigate vascular calcification development.
Summary:
- Patients received oral etidronate during dialysis sessions for 6 months.
- Aortic calcification area (ACA) showed a significant increase in the control group but remained stable in the etidronate group.
- Etidronate did not significantly alter bone mineral density or most biochemical parameters, except for serum alkaline phosphatase.
Impact:
- Etidronate demonstrates potential in inhibiting vascular calcification progression in hemodialysis patients.
- This effect may reduce the risk of cardiovascular and cerebrovascular events, improving outcomes for hemodialysis patients.
Abstract:
The progress of aortic calcification is associated with the incidence of cardiac and cerebrovascular diseases in hemodialysis patients. The present study was designed to determine whether etidronate can affect the development of aortic calcification in hemodialysis patients. Etidronate was given orally just before sleep on the day of dialysis, which was performed 2 or 3 sessions per week. Aortic calcification area (ACA), bone mineral density (BMD), and biochemical parameters were measured 6 months after the start of etidronate treatment to them compare with control. ACA in the control group showed a statistically significant increase after 6 months. However, the patients who received etidronate had no significant changes in ACA. Clinical and biochemical parameters and BMD were not influenced by etidronate treatment except serum alkaline phosphatase. These results suggest that etidronate has a potential ability to inhibit the progression of vascular calcification in hemodialysis patients, and that this beneficial effect of etidronate may prevent cardiovascular and cerebrovascular diseases that are major causes of death in hemodialysis patients.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Bone Remodeling
Skeleton and Calcium Homeostasis

